anti-14-3-3 β, pAb
Product Details | |
---|---|
Synonyms | YWHAB |
Product Type | Polyclonal Antibody |
Properties | |
Immunogen/Antigen | Recombinant human protein purified from E. coli. |
Application |
Western Blot (1:500~2,000) |
Crossreactivity |
Human Mouse Rat |
Purity Detail | Protein A purified. |
Formulation | Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol. |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
Declaration | Manufactured by AbFrontier |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
Documents | |
MSDS | No |
Product Specification Sheet | |
Datasheet |
![]() |
14-3-3, a family of acidic and soluble proteins, highly conserved in amino acid sequences from yeast to mammals, is expressed in all eukaryotic cells. Seven isoforms(β, γ, ε, eta, ζ, σ and tau/phi) encoded by seven distinct genes are identified in mammals and forms homo- and hetero- dimeric cup-shaped structures. As 14-3-3 is interacted with more than 100 binding partners, it regulates key proteins involved in various biological processes such as signal trans-duction, cell cycle, transcriptional control, cell proliferation, apoptosis, and ion channel physiology. Most 14-3-3 requires phosphorylation of serine or threonine residues in the target sequence. This protein is abundantly expressed in the brain and has been detected in the cerebrospinal fluid of patients with different neurological disorders. Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathway. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis.
1) Tzivion, G. et al. (2001) Oncogene, 20, 6331-6338. (General)
2) Tzivion, G. and Avruch, J. (2002) J.Biol.Chem. 277, 3061-3064. (General)
3) Berg, D. et al. (2003) Nat. Rev. Neurosci. 4(9), 752-762. (General)